Meeting
2019 ASCO Annual Meeting
Real-world bevacizumab utilization and outcomes in first-line ovarian cancer.
Authors
Matthew J. Monberg
Merck & Co., Inc., Kenilworth, NJ
Matthew J. Monberg , Jennifer P Hall , Rebecca Moon , Olivia Higson , Kimmie McLaurin , Tapashi Dalvi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5578)
DOI
10.1200/JCO.2019.37.15_suppl.5578
Abstract #
5578
Poster Bd #
401
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Quality Care Symposium
Real-world (RW) use of niraparib (Nir) monotherapy (mono) as first-line (1L) switch maintenance (1LSM) therapy following chemotherapy (CT) plus bevacizumab (bev) induction treatment in patients (pts) with epithelial ovarian cancer (EOC) in the SW1TCH study.
First Author: BJ Rimel
Poster
2023 ASCO Annual Meeting
Ovarian cancer and bevacizumab: Real-world use across western countries and effect on survival in high-risk subgroups.
First Author: Kristina Lindemann
Poster
2022 ASCO Annual Meeting
Real-world outcomes associated with bevacizumab combined with chemotherapy in platinum-resistant ovarian cancer.
First Author: Gordon Taylor Moffat
Poster
2022 ASCO Annual Meeting
AGO-OVAR 28/ENGOT-ov57: Niraparib versus niraparib in combination with bevacizumab in patients with carboplatin-taxane based chemotherapy in advanced ovarian cancer—A multicenter, randomized, phase III trial.
First Author: Florian Heitz